The DOI matches its Crossref record.
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis
Open accessAbstract
Background & aims Long-term ursodeoxycholic acid (UDCA) therapy slows the progression of primary biliary cirrhosis. This study examined the effect of UDCA therapy on survival free of liver transplantation in a large group of patients.Methods Data from three clinical trials were combined in which patients with primary biliary cirrhosis were randomly assigned to receive UDCA (n = 273) or placebo (n = 275). After 2 years, patients from French and Canadian studies received UDCA for up to 2 years. Patients from the American study remained on their assigned treatment for up to 4 years.Results Survival free of liver transplantation was significantly improved in the patients treated with UDCA compared with the patients originally assigned to placebo (P < 0.001; relative risk, 1.9; 95% confidence interval, 1.3-2.8). Subgroup analyses showed that survival free of liver transplantation was significantly improved in medium- and high-risk groups (serum bilirubin level, 1.4 to 3.5 or > 3.5 mg/dL; P < 0.0001 and P < 0.03, respectively) and histological stage IV subgroup (P < 0.01).Conclusions Long-term UDCA therapy improves survival free of liver transplantation in patients with moderate or severe disease. An effect in patients with mild disease is probably not found because they do not progress to end-stage disease in 4 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some studies with extended follow-up have also shown improved survival.(59,62,63)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, patients with earlier histologic stage usually respond more favorably to UDCA than patients with advanced disease, although patients with advanced disease may benefit in survival or avoid liver transplantation with this therapy.(63)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with ursodeoxycholic acid decreases the levels of the biochemical markers of cholestasis and extends the time to liver transplantation.4,5”
From A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Still being checked.
Research works printed but not linked: 7
- [2]2. Babbs C, Hunt LP, Haoubi NY, Smith A, Rowan BP, Warnes TW. sponse to ursodeoxycholic acid. Gut 1995;36:935-938. Type III procollagen peptide: a marker of disease activity and 15. Christensen E, Crowe JP, Doniach D, Popper H, Ranek L, Rode ´s prognosis in primary biliary cirrhosis. Lancet 1988;1:1021- J, Tygstrup N, Williams R. Clinical pattern and course of disease 1024. in primary biliary cirrhosis based on an analysis of 236 patients.
- [3]3. Poupon RE, Balkau B, Gue ´chot J, Heintzmann F. Predictive fac- Gastroenterology 1980;78:236-246. tors in ursodeoxycholic acid-treated patients: role of serum mark- 16.
- [4]4. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival ers of connective tissue. Hepatology 1994;19:635-640. of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994;20:701-713.
- [5]5. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic Received June 20, 1996. Accepted March 14, 1997. factor in primary biliary cirrhosis. Gut 1979;20:137-140. Address requests for reprints to: Rene ´e E. Poupon, Dr. Sci., IN- 18.
- [6]6. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance SERM Unite ´21, 16, Avenue Paul-Vaillant-Couturier, 94807 Villejuif of clinical and histological features in asymptomatic and symp- Cedex, France. Fax: (33) 01-4726-9454. tomatic primary biliary cirrhosis. N Engl J Med 1983;308:1-7. The authors thank Anne-Marie Bonnand for her helpful discussion
- [7]7. Christensen E, Neuberger J, Crowe JP, Altman DG, Popper H, and Christine Gue ´mene ´for her expert technical assistance. Portmann B, Doniach D, Ranek L, Tygstrup N, Williams R. Benefi- Presented, in part, at the 43rd Annual Meeting of the American cial effect of azathioprine and prediction of prognosis in primary Society for the Study of Liver Diseases, May 14-17, 1995, San biliary cirrhosis: final results of an international trial. Gastroenter- ology 1985;89:1084-1091.
- [8]8. Brunner of Brunner's Glands Johann Conrad Brunner (1653-1727) was born at Schaffhausen, Switzer- land, near the Rheinfall. He graduated from the university at Strasbourg, and later studied in Paris and then in England under Thomas Willis. He became a professor of anatomy at Heidelberg where he published his Disser- tatio inauguralis de glandulis duodeno intestino in 1687. Actually, Brunner's father-in-law J. J. Wepfer had previously described the glands of the duode- nal mucosa in 1679, but it was Brunner's inaugural dissertation that at- tracted attention, and hence the eponym. / 5E20$$0021 08-08-97 18:15:00 gasas WBS-Gastro
Cited by
Sorted by citations
Items 501–600 of 647
Poupon, R. Y. (2010) · EMC - Hépatologie · doi:10.1016/s1155-1976(10)46408-6 · Cited by 2
Self-citationModerne Therapie der primär biliären Cholangitis
Strassburg, C. P. (2017) · Der Internist · doi:10.1007/s00108-017-0347-4 · Cited by 2
Disease-modifying therapies and symptomatic management for primary biliary cholangitis
Patel, R., Portone, G., Lambert, J. A., Mak, S., & Alrubaiy, L. (2021) · British Journal of Hospital Medicine · doi:10.12968/hmed.2021.0247 · Cited by 2
Nguyen-Khac, É., Kairis, L., Gournay, N., Bonnière, M., Thévenot, T., Mathurin, P., HACHULLA, E., Paris, J.-C., & Dupas, J. (2004) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(04)95189-5 · Cited by 2
Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis?
Silveira, M. G., & Lindor, K. D. (2009) · Translational research · doi:10.1016/j.trsl.2009.10.006 · Cited by 2
Self-citationMonitoring and Care of the Patient Before Liver Transplantation
Sharma, P., Vargas, H. E., & Rakela, J. L. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0118-2.50037-9 · Cited by 2
Sclair, S. N., & Levy, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00042-2 · Cited by 2
Activated carbon & carbon-cryogel composites for haemoperfusion based applications
Zheng, Y. (2013) · University of Brighton Repository (University of Brighton) · Cited by 2
Rôle de l’acide ursodésoxycholique dans le traitement des cholestases de l’enfant
El‐Rifai, N., & Gottrand, F. (2004) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(04)95147-0 · Cited by 2
Methotrexate for Primary Biliary Cirrhosis: Who Is to Be Trusted?
Selmi, C. F., & Podda, M. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1435-7 · Cited by 2
Kita, Y., Sakakura, H., Hirata, M., Harihara, Y., Tanaka, H., Ito, M., Yoshino, H., Takayama, T., Kubota, K., Hashizume, K., et al. (1999) · Transplantation Proceedings · doi:10.1016/s0041-1345(99)00606-5 · Cited by 2
Transporteurs biliaires : de la génétique à la clinique
Rosmorduc, O., & Poupon, R. Y. (2004) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(04)94995-0 · Cited by 2
Self-citationPoupon, R. Y. (2010) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(10)54652-0 · Cited by 2
Self-citationPreventative therapy in primary biliary cirrhosis
Floreani, A. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00094-1 · Cited by 2
Primary biliary cirrhosis in Lithuania: diagnosis and clinical picture.
Speičienė, D., Irnius, A., Leuschner, U., Liakina, V., Semuchiniene, T., & Barakauskienė, A. (2007) · PubMed · Cited by 2
Mayo, M. J., & Thiele, D. L. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch100 · Cited by 2
Levy, C., Carrion, A. F., & Mayo, M. J. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch21 · Cited by 2
Poupon, R. Y. (2012) · Wiley eBooks · doi:10.1002/9781118321386.ch86 · Cited by 2
Self-citationMartins, A., & Levy, C. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001076 · Cited by 1
Ritter, T. E., Hanson, C., Fernandes, C. T., MacEwan, J. P., Zhao, X., Parzynski, C. S., Mercer, D., Ness, E., Wheeler, D., Kowdley, K. V., et al. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0198 · Cited by 1
Sirirattanakorn, S., Suttichaimongkol, T., Manasirisuk, W., Sawadpanich, K., Sangchan, A., Mairiang, P., Sukeepaisarnjaroen, W., & Rattananukrom, C. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103589 · Cited by 1
Current progress in our understanding of cholestasis and chronic cholestatic disorders
Papatheodoridis, G. (2007) · Annals of Gastroenterology · Cited by 1
Parés, A. R. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9644-0_35 · Cited by 1
Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, and Other Cholestatic Liver Diseases
Zein, C. O. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6643-9.00081-3 · Cited by 1
Primär biliäre Cholangitis – etablierte und neue Therapien
Vetter, M., & Kremer, A. E. (2018) · Der Internist · doi:10.1007/s00108-018-0427-0 · Cited by 1
Primär biliäre Cholangitis in Graz: Präsentation, Verlauf und Outcome
Zollner, G., Prattes, J., & Nemeth, A. (2018) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-018-0028-8 · Cited by 1
Bansal, M. B., & Friedman, S. L. (2005) · Humana Press eBooks · doi:10.1007/978-1-59259-885-4_29 · Cited by 1
Research Progress of Ursodeoxycholic Acid in the Treatment of Gallstones and Chronic Cholecystitis
姜, 慧. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.114287 · Cited by 1
Indications for Liver Transplantation
Cucchetti, A., Vukotic, R., Andreoné, P., Piscaglia, F., Pecorelli, A., Bolondi, L., Morelli, M. C., Ercolani, G., Cescon, M., Ravaioli, M., et al. (2015) · Springer eBooks · doi:10.1007/978-3-319-16997-2_6 · Cited by 1
Mécanismes moléculaires de la formation de la bile et des maladies cholestatiques
Poupon, R. Y. (2003) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)33908-1 · Cited by 2
Self-citationPrimary Biliary Cholangitis: Its Science and Practice
Wang, L., Bowlus, C. L., Wang, F., & Gershwin, M. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-50168-0_8 · Cited by 1
Laboratory Measurement of Hepatic Function
Te, H. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-40232-3.00119-9 · Cited by 1
Recurrent Primary Disease After Liver Transplantation
Saxena, V., & Terrault, N. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00053-7 · Cited by 1
Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis
Ahn, D. (2020) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2020.25.2.107 · Cited by 1
Croome, K. P., & Taner, C. B. (2020) · Springer eBooks · doi:10.1007/978-3-030-46470-7_12 · Cited by 1
Tanaka, A., & Gershwin, M. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00058-0 · Cited by 2
Biologie des Maladies Cholestatiques Chroniques de l' Adulte
Chazouillères, O. (2007) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(07)80301-7 · Cited by 2
Ursodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective
Gao, W., Li, Z., Chu, H., Yuan, H., Hu, L., Yao, L., Zhang, L. R., Wang, W., Lin, R., & Yang, L. (2022) · Springer eBooks · doi:10.1007/978-981-19-2615-0_6 · Cited by 1
Reichel, C., Renner, E. L., & Meier-Abt, P. (2000) · pharma-kritik · doi:10.37667/pk.1999.318 · Cited by 1
Liver Diseases in Patients with Inflammatory Bowel Diseases
Cullen, S., & Chapman, R. W. (2010) · Wiley eBooks · doi:10.1002/9781444318418.ch36 · Cited by 1
Markov models in primary biliary cirrhosis
Talwalkar, J. A. (2002) · Gastroenterology · doi:10.1053/gast.2002.36878 · Cited by 1
Poupon, R. Y. (2010) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(10)70489-x · Cited by 1
Self-citationAssociation polyarthrite rhumatoïde et cirrhose biliaire primitive
Caramella, C., Avouac, J., Sogni, P., Puéchal, X., Kahan, A., & Allanore, Y. (2007) · Revue du Rhumatisme · doi:10.1016/j.rhum.2006.06.017 · Cited by 1
Examining the increased IgM production and ursodeoxycholic acid treatment in PBC
Lazaridis, K. N., & LaRusso, N. F. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.040 · Cited by 1
Drug therapy of primary biliary diseases: classical and modern strategies
Schlichting, J., & Leuschner, U. (2001) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2001.tb00144.x · Cited by 1
van Weel, C. (2004) · PubMed · Cited by 1
Ursodeoxycholic acid-disulphate (SUDCA) — a potent chemopreventive agent against colon cancer
Setchell, K. D. R., Brown, N. M., & Bove, K. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6252-0_27 · Cited by 1
Primary Biliary Cholangitis (Formerly Primary Biliary Cirrhosis)
Trivedi, P. J., & Hirschfield, G. M. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch38 · Cited by 1
Strassburg, C. P., Lüttig, B., & Manns, M. P. (2000) · Springer eBooks · doi:10.1007/978-3-642-57194-7_49 · Cited by 1
Significance of antimitochondrial antibody profiles in primary biliary cirrhosis
Klein, R., & Berg, P. A. (1998) · Springer eBooks · doi:10.1007/978-94-011-4884-9_4 · Cited by 1
Heathcote, E. J., & Milkiewicz, P. (2007) · Wiley eBooks · doi:10.1002/9780470691861.ch11a · Cited by 1
Self-citationNatural history models of primary biliary cirrhosis
Kim, W. R., & Dickson, E. R. (1998) · Springer eBooks · doi:10.1007/978-94-011-4884-9_9 · Cited by 1
Self-citationAutoimmune Liver Diseases in Canterbury, New Zealand
Ngu, J. H. (2013) · Otago University Research Archive (University of Otago) · Cited by 1
10 Cholestatische leverziekten
Beuers, U. H., Rauws, E. A., ter Borg, P. C. J., van Buuren, H. R., & Koek, G. H. (2009) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-7437-3_10
Management of the Patients with Feature of Autoimmune Hepatitis
Abe, K., Takahashi, A., & Ohira, H. (2014) · Springer eBooks · doi:10.1007/978-4-431-54789-1_20
Gender-Specific Issues in Liver Diseases
Conjeevaram, H. S. (2004) · Principles of Gender-Specific Medicine · doi:10.1016/b978-012440905-7/50312-1
New clinical trials in primary biliary cirrhosis: design and endpoints
Everhart, J. E. (1998) · Springer eBooks · doi:10.1007/978-94-011-4884-9_20
Orphan drugs in development for primary biliary cirrhosis: challenges and progress
Lindor, K. D., Ali, A. H., & Byrne, T. (2015) · Orphan Drugs Research and Reviews · doi:10.2147/odrr.s69477
Self-citationChapter 12 Primary Biliary Cirrhosis
Abdalian, R., & Heathcote, J. (2008) · Technical report · doi:10.1016/s1571-5078(07)00012-8
Dancygier, H. (2009) · Springer eBooks · doi:10.1007/978-3-642-04519-6_19
Müllhaupt, B., & Smith, A. D. (2006) · Wiley eBooks · doi:10.1002/9780470751541.ch10
Poupon, R. Y. (2011) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(11)70560-5
Self-citationA case of primary biliary cirrhosis: First report from Bangladesh
Mamun-Al-Mahtab, M.-A.-M., Uddin, K., Rahman, S., Khan, M., Kamal, Bhuiyan, M., & Hussain, G. (2010) · Clinical and Experimental Medical Journal · doi:10.1556/cemed.4.2010.1.18
Biologie des maladies cholestatiques chroniques de l’adulte
Lemoinne, S., & Chazouillères, O. (2017) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(17)30077-1
Évaluation de l'incidence de la cirrhose biliaire primitive en 2007 en France
Johanet, C., Gaouar, F., Sallé, A.-V., Diemert, B., Ballot, E., Chazouillères, O., Carrat, F., Poupon, R. Y., & Corpechot, C. (2008) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(08)71574-0 · Cited by 1
Self-citationL’atteinte osseuse dans les maladies chroniques cholestatiques
Gars, L. L. (2002) · Revue du Rhumatisme · doi:10.1016/s1169-8330(02)00369-1
Anti-inflammatory Effects of UDCA on Splenocytes Exposed to PMA/Ionomycin
Park, S., Woo, J.-S., Jung, Y., Won, T., Hih, Y.-J., Lee, C.-W., Kim, H.-S., Joo, S.-S., Lee, D.-I., & Hwang, K. (2008) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2008.16.2.126
Benner, K. G. (1999) · Liver Transplantation and Surgery · doi:10.1002/lt.500050403
Autoimmune liver diseases: internist’s guide from bench to bedside
Visconti, M. (2015) · Italian Journal of Medicine · doi:10.4081/itjm.2015.508
Clark, V., & Levy, C. (2007) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0741
Treatment of primary biliary cirrhosis
Poupon, R. Y., & Corpechot, C. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.870031
Self-citationMedikamentöse Therapie der Komplikationen der Leberzirrhose
Grünhage, F., Heller, J., Appenrodt, B., Schmitz, V., & Sauerbruch, T. (2007) · Der Internist · doi:10.1007/s00108-007-1965-z
Primary Biliary Cirrhosis: Present and Future
Trianos, C., & Avgerinos, A. (2006) · Annals of Gastroenterology
Therapy of primary sclerosing cholangitis
Beuers, U. H., & Paumgartner, G. (2000) · Springer eBooks · doi:10.1007/978-94-011-4000-3_29
Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines
Cowin, G., Jonsson, J. R., McPherson, S., Clouston, A. D., Benson, M. D., Powell, E. E., & Galloway, G. J. (2009)
La cirrhose biliaire primitive : actualités
Corpechot, C. (2013)
Primär biliäre Zirrhose: Diagnostik und Therapie
Schönfeld, J. V., Breuer, N. F., & Goebell, H. (1998) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/bf03042679
Ursodeoxycholic acid in liver diseases
Juszczyk, J. (2012) · Gastroenterology Review · doi:10.5114/pg.2012.29879
石橋, 大. (2004) · 医療 = Japanese journal of National Medical Services : 国立医療学会誌 · doi:10.11261/iryo1946.58.67
Liver Transplantation for Primary Biliary Cirrhosis
Talwalkar, J. A., Kim, W. R., & Dickson, E. R. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0118-2.50017-3
Self-citationBoberg, K. M. (2009) · NORA - Norwegian Open Research Archives
Recurrence of Primary Biliary Cirrhosis Following Liver Transplantation
Wiesner, R. H. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2947-4_5
Role of side-chain amidation for the anticholestatic action of nourursodeoxycholic acid in rat liver
Maitz, S. B., Denk, G., Wimmer, R., Rust, C., Invernizzi, P., Ferdinandusse, S., Wanders, R. J. A., Fuchsbichler, A., Fickert, P., Trauner, M., et al. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9644-0_22
Medical Therapy of Cholestatic Liver Diseases
Rust, C., & Beuers, U. H. (2010) · Springer eBooks · doi:10.1007/978-1-4419-9034-1_24
Features, prognosis and management of primary biliary cirrhosis in the era of ursodeoxycholic acid
Poupon, R. Y., Chazouillères, O., Chrétien, Y., & Corpechot, C. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9644-0_37
Self-citationKaplan, M. M. (2004) · Encyclopedia of Biological Chemistry · doi:10.1016/b0-12-443710-9/00045-4
Carey, E. J., Rakela, J. L., & Vargas, H. E. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-0268-8.00036-1
Targets and investigative treatments for primary biliary cholangitis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1227240
Self-citationMyers, R. P. (2008) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/21267
Autoimmune Liver Diseases: Primary Biliary Cholangitis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-30103-7_16
Self-citationTreatment of chronic cholestasis: What we know and what we will know?
Boyer, J. L. (2016) · Clinical Liver Disease · doi:10.1002/cld.591
Chronic cholestatic liver diseases
Waldum, H. L., Bjornsson, E. S., & Brenna, E. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1296276
Ursodeoxycholic acid for primary biliary cirrhosis: lesson for the future?
Bogdanos, D. P., Grasso, A., Okamoto, M., Butler, P., & Williams, R. L. (2000)
Therapy of primary biliary cirrhosis
Poupon, R. Y., Corpechot, C., & Poupon, R. E. (2000) · Springer eBooks · doi:10.1007/978-94-011-4000-3_28
Self-citationCarey, E. J., & Levy, C. (2018) · Clinics in Liver Disease · doi:10.1016/s1089-3261(18)30044-8
Advances in treatment options for patients with primary biliary cholangitis
Parés, A. R. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1394840
Abdalian, R., Heathcote, J., & Ramos‐Casals, M. (2017) · Technical report · doi:10.1016/b978-0-444-63707-9.00005-2
Transition from Conventional Drugs to Promising Drugs for Primary Biliary Cholangitis
Dohmen, K. (2017) · Advanced Research in Gastroenterology & Hepatology · doi:10.19080/argh.2017.04.555634
Huet, P., Vincent, C., Deslaurier, J., Côté, J., Matsutami, S., & Boileau, R. (2008)
Metadata
- Authors
- Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E.
- Affiliations
- Mayo Clinic (US)
- Inserm (FR)
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 1997-09
- Volume
- 113
- Issue
- 3
- Pages
- 884-890
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2071394537
- Semantic Scholar
- b05e12d331fd48ec432f894f09036aaff9a53c62
- Cited by
- 648
- References
- 0
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 15 · 2023: 9 · 2022: 5 · 2021: 15 · 2020: 21 · 2019: 23 · 2018: 27 · 2017: 26 · 2016: 12 · 2015: 24 · 2014: 26 · 2013: 13 · 2012: 17
- FWCI
- 21.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- ursodeoxycholic acid, primary biliary cirrhosis, liver transplantation, disease severity, serum bilirubin, subgroup analysis, treatment efficacy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cause of Death, Female, Forecasting, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Postoperative Care, Severity of Illness Index, Ursodeoxycholic Acid, Survival Analysis, Liver Transplantation, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
